FDA Approves Lynparza Combo as First-line Maintenance Therapy for Advanced Ovarian Cancer

FDA Approves Lynparza Combo as First-line Maintenance Therapy for Advanced Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. This indication also includes patients who have advanced fallopian tube or primary peritoneal cancer. HRD-positive tumors — present in one of every two women with advanced ovarian cancer — have mutations in certain genes involved in DNA repair, including the BRCA genes, and/or genomic instability (a high frequency of mutations within the genome). Since these tumors rely on other DNA repair mechanisms mainly involving the PARP enzyme — a DNA damage sensor — they are more likely to respond to therapies blocking PARP activity (PARP inhibitors), such as Lynparza. Patients’ eligibility for this combination therapy will be evaluated using the
Subscribe or to access all post and page content.